학술논문
Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation
Document Type
Abstract
Author
Source
In Blood 29 November 2018 132 Supplement 1:4666-4666
Subject
Language
ISSN
0006-4971